Temsirolimus results in good but short-duration responses in primary CNS lymphoma

Single-agent therapy with temsirolimus was active in patients with relapsed/refractory primary central nervous system lymphoma, but most of the responses were short lived, results of a phase II trial...
Source: Clinical Neurology News - Category: Neurology Source Type: news